Abstract: The present disclosure provides a novel compound effective in antagonizing EP4, which is a compound represented by Formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by Formula I: wherein: R1 is selected from —CH3, —CHF2, and —CF3; R2 is selected from C2-C6 alkyl, C3-C6 cycloalkyl, C2-C6 halogen-substituted alkyl, C3-C6 halogen-substituted cycloalkyl; R3 is selected from hydrogen, halogen, C1-C2 alkyl, C1-C2 fluorine- or chlorine-substituted alkyl; R4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxyl, C1-C6 halogen-substituted alkyl, C1-C6 halogen-substituted alkoxyl.

Abstract: An application of HJT aqueous extract in the preparation of drugs against a Blue-ear disease is provided. For the first time, it is found in the present invention that HJT extract has a significant effect of preventing and treating the Blue-ear disease. Specifically, through experiments of qRT-PCR and immunofluorescence techniques, the present invention has proved that HJT extract can significantly inhibit infection and replication of PPRSV with significant antiviral effect, so that it is expected to become a new type of biologically active substance for prevention and treatment of Blue-ear disease. The product prepared by the method can be used as natural antiviral drugs for the prevention and treatment of the Blue-ear disease, realizes the comprehensive utilization of HJT plants, and improves its value, which has a good application prospect.

Abstract: Some embodiments of the invention provide a method for a first security controller that performs security operations on the packets that are transmitted within a network. The method of some embodiments receives a packet from a forwarding element in the network based on a decision made by a security agent that operates along with the forwarding element. When the first security controller stores a security rule for the packet, the method processes the packet according to the stored security rule. When the first security controller does not store a security rule for the packet, the method (i) determines that a second security controller stores a security rule for the packet based on a set of header values of the packet, and (ii) sends the packet to the second security controller for security processing according to the security rule for the packet stored on the second security controller.

Abstract: Embodiments of the present disclosure provide an opening and closing mechanism and a leakage protection device. The opening and closing mechanism comprises: a stationary contact and a movable contact, which contacts the stationary contact at ON-position and separates from the stationary contact at OFF-position; a first magnetic assembly; and a second magnetic assembly that is integrally rotatable about an axis, the second magnetic assembly comprising: an electric conductor onto which the movable contact is mounted; and a magnetic body comprising at least one magnetic portion configured to rotate about the axis under a magnetic force from the first magnetic assembly, to correspondingly drive the movable contact to rotate between the ON-position and the OFF-position, wherein a distance from each of the at least one magnetic portion to the axis is smaller than a distance from the movable contact to the axis.

Abstract: An apparatus comprises means for: obtaining a navigation path (2) between two locations (4, 6) which are separated by an obstacle (8), the navigation path (2) comprising an original vertex (10); modifying the navigation path (2) to comprise a displaced vertex (12), the displaced vertex (12) being displaced from the original vertex (10) in a direction away from a part of the obstacle (8) which is nearest to the original vertex (10); and smoothing a section of the navigation path (2) which passes via the displaced vertex (12). The smoothing of the section forms a curved path section (16) in the navigation path (2). The curved path section (16) comes no closer to the obstacle (8) than the original vertex (10).

Abstract: A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase allosteric inhibitor or a pharmaceutically acceptable salt thereof in the preparation of drugs for the treatment of tumor diseases.

Abstract: The present invention relates to new medicine application of p-hydroxyphenylpropionic acid. Experiments prove that p-hydroxyphenylpropionic acid has a remarkable pharmacological effect in inhibiting respiratory tract infection, particularly inhibiting pulmonary edema, inflammatory cell infiltration and cell apoptosis in lung injury and delaying lung function degradation of mice. Therefore, the present invention discloses the application of p-hydroxyphenylpropionic acid to prepare a medicine for preventing and treating respiratory tract infection, particularly pneumonia, pulmonary edema or pulmonary epithelial and/or endothelial cell necrosis in lung injury for the first time.

Abstract: The disclosure relates to an expression method of a Haemocoagulase Acutus (Halase) recombinant protein. The method includes the following steps: (1) optimizing a halase gene; (2) performing Polymerase Chain Reaction (PCR) amplification on an optimized halase gene; (3) constructing an Agkis-pMCX expression vector, transforming plasmids to competent cells of an Escherichia coli for amplification, screening in an Amp-resistant manner for positive cloning, sequencing and extracting recombinant plasmids with correct sequencing; (4) transfecting recombinant plasmids to CHO cells; and (5) expressing the recombinant protein and identifying. According to the expression method, a recombinant halase is expressed first using the CHO cells cultured in a serum-free suspension manner; and by utilizing a bioengineering means, the actual production problems of insufficient raw material sources and unstable quality of a snake venom product are solved successfully.

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).

Abstract: The present disclosure relates to an intravascular stent, preparation method and use thereof, and the intravascular stent comprises a positioning segment and a supporting segment, the positioning segment comprising a plurality of first repeating elements, the supporting segment comprising at least two supporting units and at least one connecting unit, the supporting unit comprising a plurality of second repeating elements, the number of the first repeating elements differing from the number of the second repeating elements, a plane formed by front ends of the plurality of first repeating elements being vertical to or intersecting with the axis of the intravascular stent. The intravascular stent of the present disclosure is particularly suitable for iliac vein, with good supporting effect for iliac vein and less damage to venous wall, and can effectively avoid forming in-stent secondary thrombosis after intravascular stent implantation.

Abstract: A thrombus treatment platform comprises an aspiration catheter, an aspiration pump, a stirring device and a filter assembly, the filter assembly comprises a filter rod and a filter screen; the stirring device comprises a first catheter, a second catheter, a stirrer and an operating device capable of causing the first catheter and the second catheter to slide relatively so that the stirrer can be switched between the expanded state and the collapsed state; the thrombus treatment platform further comprises a driving device capable of driving the rotation of the stirrer. The present disclosure can remove thrombus under the condition of ensuring relative safety, and is particularly suitable for removing a large number of thrombus in the inferior vena cava, protects venous valves and venous vessel walls, has controllable blood loss and simple operation steps, shortens operation time, and reduces patient hospitalization expenses.

Abstract: Provided is a compound. The compound is a compound represented by formula (A), or a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula (A), where R is R1 and R2 are each independently selected from H, C1-C10 alkyl, C3-C10 cycloalkyl, C1-C10 alkoxyl, halogen, and —CN; and R3, R4, and R5 are each independently selected from C1-C10 alkyl, C3-C10 cycloalkyl, C1-C10 alkoxyl, halogen, and —CN, under a premise that: if R1 is —CH3, C1, or —CN, R2 is not H, and if R1 is H, R2 is not H, —CN, or —CH3.

Abstract: Disclosed is a new drug application of a Pithecellobium Clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter Baumannii (MDRAB), an MDR Pseudomonas Aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli (ECO) and an ESBL-producing Klebsiella Pneumonia (KPN).

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).

Abstract: An apparatus comprising: at least one processor; and at least one memory including computer program code; the at least one memory and the computer program code configured to, with the at least one processor, cause the apparatus at least to perform: receiving at least one signal comprising control information; determining data to transmit using grant-free data transmission; determining whether grant-free data transmission using time-frequency repetition is permitted for the grant-free data transmission in dependence on the received control information; if it is determined that use of time-frequency repetition for the grant-free data transmission is permitted, causing transmission of grant-free data transmission using time-frequency repetition; and if it is determined that use of time-frequency repetition for the grant-free data transmission is not permitted, causing transmission of grant-free data transmission without using time-frequency repetition.

Abstract: Disclosed is a new drug application of a Pithecellobium Clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter Baumannii (MDRAB), an MDR Pseudomonas Aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli (ECO) and an ESBL-producing Klebsiella Pneumonia (KPN).

Abstract: Methods, devices and computer readable storage medium for ranging between a tag device (410) and plurality of anchor devices (405). The tag device (410) broadcasts a first poll message (605) to a plurality of anchor devices (405). The tag device (410) receives a plurality of response messages (620) for the first poll message (605) from the plurality of anchor devices (405). The plurality of response messages (620) are transmitted by the plurality of anchor devices (405) at a plurality of response time points. The plurality of response time points are associated with ranks of respective distances among a plurality of distances between the tag device (410) and the plurality of anchor devices (405). After receiving the plurality of response messages, the tag device (410) broadcasts a second poll message to the plurality of anchor devices (405). The ranging efficiency may be improved.

Abstract: The present invention provides a method and apparatus for assigning user equipment HARQ time and base station HARQ time in a radio communication network, wherein the user equipment HARQ time is for the user equipment to process the HARQ process, the base station HARQ time is for the base station to process the HARQ process, the user equipment HARQ time being longer than the base station HARQ time.

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).